This can be another avenue to tell the public what needs changed for the people.
All have a Healthcare Section to give ideas.
You might want to include information of how they are keeping us sick, why they are keeping us sick.
Including the 1980 decision to patent and profit from live organisms.
Most do not know that same year was when they let the oil companies into the pockets of the regulators.
http://web.ead.anl.gov/dwm/regs/federal/epa/index.cfm Hazardous Waste Exemption for Oil and Gas Exploration and Production Wastes.
In 1980, Congress conditionally exempted oil and gas exploration and production (E&P) wastes from the hazardous waste management requirements of Subtitle C of the Resource Conservation and Recovery Act (RCRA) (Section 3001(b)(2)(A) of RCRA and Section 8002(m) of RCRA).
In addition to directing the EPA to study these wastes and submit a report to Congress on the status of their management, Congress required the Agency either to promulgate regulations under Subtitle C of RCRA or make a determination that such regulations were unwarranted.
------------------------------------------------
It is the logical culmination of a path first opened by the U.S. Supreme Court’s Diamond v. Chakrabarty ruling in 1980, which authorized the patenting of live, genetically altered microorganisms.
The patenting of living organisms opened the way for an ecologically and ethically dubious future in which the life forms that are part of the sacred web of life can be owned and treated as commodities.
Knowledge is treated as a proprietary investment, not as a public good. This ethic has enabled Harvard University to become the proud owner of a transgenic mouse injected with a cancer gene, the so-called “onco-mouse,” which is used in laboratory experiments.
Interestingly, the Canadian courts have refused to recognize this patent.
New barriers to sharing. One inevitable result of all these new ownership claims is the rise of new
barriers to open sharing, collaboration and discovery. Patents are increasingly being granted for “upstream” research, which means that basic knowledge that everyone else must use for the field to advance, is becoming proprietary.
Harvard, MIT and the Whitehead Institute, for example, have a patent on all drugs that inhibit something known as NF-kB cell signaling.
Since this physiological process is believed to have something to do with many diseases such as cancer and osteoporosis, the patent deters others from pursuing their own scientific investigations in this area.
http://www.nsf.gov/statistics/nsb0803/start.htm
In addition, in this century the industry share of support for basic research in universities and colleges, the primary performers of U.S. basic research, has also been declining.
Likewise, Federal Government support for academic R&D[3] began falling in 2005 for the first time in a quarter century, while Federal and industry support for their own basic research has stagnated over the last several years.
These trends are especially alarming in light of the growing importance of knowledge-based industries in the global economy.
